VANCOUVER, Oct. 25 /CNW/ - Biotech Holdings (the "Company", OTC BB:
BIOHF.OB) reports that it has signed an agreement, with a private company
based in El Salvador for marketing and distribution of its Sucanon Type II
diabetes drug in four Central American countries, Guatemala, Honduras,
Nicaragua and El Salvador.
The four new markets targeted in connection with this agreement have a
total population of approximately 33 million people, with an estimated 775,000
cases of Type II Diabetes in the region.
The Central American markets will be served by Sucanon deliveries from
the Company's contract-packager, based in Mexico City. The distributor will
co-ordinate its advertising in the Central American region with advertising
arranged by Biotech's office in Mexico.
This release has been approved by the Board of Directors of Biotech
Robert B. Rieveley, Pres.
On behalf of the Board of Directors
Phone: 604 295 1119
Any statements made in this release that are not based on historical fact
are forward-looking statements. Any forward-looking statements made in this
release represent management's best judgement as to what may occur in the
future. However, actual outcome and results are not guaranteed and are subject
to certain risks, uncertainties and assumptions and may differ materially from
what is expressed. There is no assurance that regulatory approval will be
obtained in any specific market nor any assurance that sales, once begun, will
For further information:
For further information: Austin Rand at Biotech Holdings,
1-888-216-1111, or email@example.com; For background information on Biotech
Holdings, or to receive news updates, see www.biotechltd.com